悬赏1000虎币Hey Tigers!
Do you notice Pfizer's new play?
Pfizer announced its acquisition of Arena Pharmaceuticals today in a $6.7 billion deal for the company’s research on inflammatory conditions affecting the stomach and intestine. Pfizer will pay Arena $100/share in cash.
Shares of Arena stock nearly doubled yesterday as the company pursues treatments for ulcerative colitis and Crohn’s disease, as well as other dermatological, gastrointestinal, and cardiac conditions — Arena’s etrasimod drug for ulcerative colitis/Crohn’s is currently in late-stage trials. The acquisition’s timing is no coincidence as Pfizer also investigates treatments for gastrointestinal conditions.
Pfizer is on a roll, lately. In addition to the obvious success of the company’s COVID-19 vaccine, Pfizer also acquired the immuno-oncology company Trillium Therapeuticslast month to scale its blood cancer research. The Arena acquisition will boost Pfizer’s proficiency in gastroenterology, dermatology, and cardiology.
If etrasimod’s late-stage data is promising, Wells Fargo analysts estimate the drug could rake in as much as $2.5 billion in sales.
Is this a successful acquisition?
You may be rewarded with Tiger Coins💸💸💸
Don't forget I am the richest tiger in this community😎😎
精彩评论
$辉瑞(PFE)$ 辉瑞对Arena制药的收购将增加辉瑞在胃肠病学、皮肤病学和心脏病学领域的药物库。这肯定是红利增值。与去年相比，辉瑞的收入增长了129%，销售额飙升至240.9亿美元，达到134%。仅辉瑞的疫苗销售就带来了12美元。980亿的销售额。只是太神奇了！辉瑞的股价也一直炙手可热。现在就买辉瑞，因为它将呈指数级增长！加油，辉瑞！🚀🚀🚀🌙🌙🌙
@MillionaireTiger --辉瑞收购竞技场